An interventional study of Albumin Human in Septic Shock, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-06-06.
Sponsored by Egymedicalpedia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Shock, Septic with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Shock, Septic · Egypt.
Among the 61 studies in Shock, Septic with a site in Egypt, this one is the 24th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 40th registered.
1,082 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →16 of the 61 studies in Shock, Septic with a site in Egypt are open now. Recruiting first, the newest first:
Menoufia University · Sites in Egypt
Ages 18+
Menoufia University · Sites in Egypt
Ages 1 mo–18 yrs
Alexandria University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18–50
Ain Shams University · Sites in Egypt
Ages 1 mo–16 yrs · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 11 · Phase 4 7
First in 2016; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 60 across the 37 interventional studies, 65 across the 24 observational. Of the 32 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 61 have an industry lead sponsor. The 10 most frequent:
Egymedicalpedia is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Egymedicalpedia has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
5 of the studies in Shock, Septic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07245550Assiut UniversityThyroid and Adrenal Disorders in ICU | 2026-12-01 |
| NCT07516236Menoufia UniversityDynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock | 2027-01 |
| NCT07706413Menoufia UniversityPlasma Exchange in Children With Severe Sepsis and Septic Shock | 2027-02-28 |
| NCT07716956Alexandria UniversityEffect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients | 2027-04 |
| NCT07321405Assiut UniversityAssessment of Cardiac Output and Stroke Volume in Septic Shock Patients | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Shock, Septic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock.
An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions.
Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions.
Colloid solutions are composed of various amounts of substances, for instance, albumin, hydroxyethyl starch, dextran, and gelatine. Although the current international guidelines from the Surviving Sepsis Campaign recommend crystalloids to perform the initial resuscitation, and the replacement with albumin on patients who require substantial amounts of crystalloids, the choice of the best type of resuscitation fluids is still under debate.
Albumin, in addition to its oncotic functions, has a variety of other properties, including binding and transport of various endogenous molecules, anti-inflammatory and anti-oxidative effects, and modulation of nitric oxide metabolism.These properties are particularly relevant in critically ill patients, especially in patients with sepsis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
About 23 patients will be objected for resuscitation with 60 gm (300 ml) human albumin 20% (HA 20%) over 2-3 hours combined usual practice with 30 ml/kg crystalloid.
Drug: Albumin Human
About 23 patients will be objected for resuscitation with 30 ml/kg crystalloid.
Drug: Albumin Human
To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
Also known as: crystalloids
Recovery from shock
A reversal of hypotension (MAP) at the end of the first three hours of the resuscitation period.
Time frame: 3 Hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Nov 2024, 5 months after the start.
Of 173 interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human